[Skip to Navigation]
Sign In

October 2021 - April 2016

Decade

Year

Issue

February 2020, Vol 5, No. 2, Pages 119-236

In This Issue of JAMA Cardiology

Highlights

Abstract Full Text
free access
JAMA Cardiol. 2020;5(2):119. doi:10.1001/jamacardio.2019.3439
Original Investigation

Safety and Efficacy of Femoral Access vs Radial Access in ST-Segment Elevation Myocardial Infarction: The SAFARI-STEMI Randomized Clinical Trial

Abstract Full Text
free access
JAMA Cardiol. 2020;5(2):126-134. doi:10.1001/jamacardio.2019.4852

This multicenter randomized clinical trial conducted in Canada assesses whether 30-day all-cause mortality differs with the use of radial access or femoral access for primary percutaneous coronary intervention among referred patients with ST-segment elevation myocardial infarction.

Temporal Trends in Racial Differences in 30-Day Readmission and Mortality Rates After Acute Myocardial Infarction Among Medicare Beneficiaries

Abstract Full Text
free access
JAMA Cardiol. 2020;5(2):136-145. doi:10.1001/jamacardio.2019.4845

This cohort study assesses temporal trends in 30-day readmission and mortality rates among black and nonblack patients discharged after hospitalization for acute myocardial infarction at hospitals defined as low-performing and high-performing per their Hospital Readmissions Reduction Program penalty status.

Association Between Change in Circulating Progenitor Cells During Exercise Stress and Risk of Adverse Cardiovascular Events in Patients With Coronary Artery Disease

Abstract Full Text
free access
JAMA Cardiol. 2020;5(2):147-155. doi:10.1001/jamacardio.2019.4528

This cohort study of 454 patients with stable coronary artery disease investigates the association between the change in circulating progenitor cell counts during exercise and the risk of adverse cardiovascular events among patients with and without stress-induced myocardial ischemia.

Utility of 90-Day Mortality vs 30-Day Mortality as a Quality Metric for Transcatheter and Surgical Aortic Valve Replacement Outcomes

Abstract Full Text
free access has audio
JAMA Cardiol. 2020;5(2):156-165. doi:10.1001/jamacardio.2019.4657

This cohort study of Medicare beneficiaries compares 30-day vs 90-day mortality as a hospital performance metric for transcatheter aortic valve replacement and surgical aortic valve replacement.

Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C

Abstract Full Text
free access
JAMA Cardiol. 2020;5(2):167-174. doi:10.1001/jamacardio.2019.4748

This case series examines the association between use of hearts from hepatitis C–positive donors for US patients undergoing heart transplant and heart transplant volumes, wait-list duration, the transmission and cure of donor-derived hepatitis C, and morbidity and mortality at 1 year.

Neurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices

Abstract Full Text
free access
JAMA Cardiol. 2020;5(2):175-182. doi:10.1001/jamacardio.2019.4965

This registry-based cohort study analyzes the association between varying combinations of neurohormonal blockade therapies and survival and quality of life in adult patients with left ventricular assist devices.

Association of Longitudinal Trajectory of Albuminuria in Young Adulthood With Myocardial Structure and Function in Later Life: Coronary Artery Risk Development in Young Adults (CARDIA) Study

Abstract Full Text
free access
JAMA Cardiol. 2020;5(2):184-192. doi:10.1001/jamacardio.2019.4867

This cohort study describes the trajectory of albuminuria as measured by urine albumin-to-creatinine ratio across a 20-year span and evaluates the association of albuminuria trajectory with echocardiographic indices of structure and function in middle age.

Age-Related Differences in the Noninvasive Evaluation for Possible Coronary Artery Disease: Insights From the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) Trial

Abstract Full Text
free access
JAMA Cardiol. 2020;5(2):193-201. doi:10.1001/jamacardio.2019.4973

This prespecified analysis of the PROMISE randomized clinical trial determines whether the prognostic utility of anatomic vs functional testing for coronary artery disease varies based on patient age.

Brief Report

Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial

Abstract Full Text
free access has active quiz
JAMA Cardiol. 2020;5(2):202-207. doi:10.1001/jamacardio.2019.4665

This secondary analysis of the PIONEER-HF trial explores the association between patients with chronic heart failure switching from taking enalapril to taking sacubitril/valsartan with N-terminal pro–B-type natriuretic peptide levels.

Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention

Abstract Full Text
free access
JAMA Cardiol. 2020;5(2):209-215. doi:10.1001/jamacardio.2019.4759

This cohort study examines the drug eligibility of 12 cardiovascular drugs recently tested in several randomized clinical trials for Danish patients with known ischemic heart disease or prior myocardial infarction.

Viewpoint

Leveraging the Power of Marginal Gains to Improve Outcomes in Interventional Cardiology

Abstract Full Text
JAMA Cardiol. 2020;5(2):121-123. doi:10.1001/jamacardio.2019.4278

This Viewpoint examines the ability of a marginal gains approach to improve interventional outcomes in cardiology.

From the Heart

The David Sign

Abstract Full Text
JAMA Cardiol. 2020;5(2):124-125. doi:10.1001/jamacardio.2019.4874

This article describes an observation of jugular venous distention in Michelangelo’s David and its relevance to clinical cardiology.

Invited Commentary

Comparing Percutaneous Coronary Intervention Access Sites for ST-Elevation Myocardial Infarction—Are Radial and Femoral Access Equally Safe?

Abstract Full Text
JAMA Cardiol. 2020;5(2):134-135. doi:10.1001/jamacardio.2019.5356

Racial Disparities in Readmission Rates Following Acute Myocardial Infarction in the Hospital Readmissions Reduction Program Era

Abstract Full Text
JAMA Cardiol. 2020;5(2):145-146. doi:10.1001/jamacardio.2019.5120

Ninety-Day Outcome Assessment After Transcatheter and Surgical Aortic Valve Replacement—Is the Juice Worth the Squeeze?

Abstract Full Text
has audio
JAMA Cardiol. 2020;5(2):165-166. doi:10.1001/jamacardio.2019.4821

Early Implementation of Sacubitril/Valsartan for Patients With Heart Failure

Abstract Full Text
JAMA Cardiol. 2020;5(2):207-208. doi:10.1001/jamacardio.2019.4822

Translating the Secondary Prevention Therapeutic Boom Into Action

Abstract Full Text
JAMA Cardiol. 2020;5(2):215-216. doi:10.1001/jamacardio.2019.4959
Special Communication

Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action

Abstract Full Text
JAMA Cardiol. 2020;5(2):217-229. doi:10.1001/jamacardio.2019.5173

This guideline presents updated recommendations for management of familial hypercholesterolemia.

JAMA Cardiology Clinical Challenge

Wide Complex Tachycardia in a Woman in Her 30s With Electrolyte Derangements

Abstract Full Text
has active quiz has multimedia
JAMA Cardiol. 2020;5(2):230-231. doi:10.1001/jamacardio.2019.4838

This case report describes a woman with active bulimia, syncope after palpitations, and an abnormal heart rhythm. What would you do next?

Comment & Response

Questioning the Benefit of Statins for Low-risk Populations—Medical Misinformation or Scientific Evidence?

Abstract Full Text
JAMA Cardiol. 2020;5(2):233. doi:10.1001/jamacardio.2019.5117

Questioning the Benefit of Statins for Low-Risk Populations—Medical Misinformation or Scientific Evidence?—Reply

Abstract Full Text
JAMA Cardiol. 2020;5(2):233-234. doi:10.1001/jamacardio.2019.5123

Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older

Abstract Full Text
JAMA Cardiol. 2020;5(2):234. doi:10.1001/jamacardio.2019.5197

Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older

Abstract Full Text
JAMA Cardiol. 2020;5(2):235. doi:10.1001/jamacardio.2019.5200

Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older—Reply

Abstract Full Text
JAMA Cardiol. 2020;5(2):235-236. doi:10.1001/jamacardio.2019.5241
Editor's Note

Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits After LVAD Placement?—A Call for a Randomized Clinical Trial

Abstract Full Text
JAMA Cardiol. 2020;5(2):183. doi:10.1001/jamacardio.2019.5019
Correction

Incorrect Degree for Second Author in Byline

Abstract Full Text
free access
JAMA Cardiol. 2020;5(2):236. doi:10.1001/jamacardio.2020.0045
JAMA Cardiology Masthead

JAMA Cardiology

Abstract Full Text
free access
JAMA Cardiol. 2020;5(2):120. doi:10.1001/jamacardio.2019.3440
×